1. Home
  2. GAME vs VERU Comparison

GAME vs VERU Comparison

Compare GAME & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GameSquare Holdings Inc.

GAME

GameSquare Holdings Inc.

HOLD

Current Price

$0.32

Market Cap

44.4M

Sector

N/A

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.57

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAME
VERU
Founded
2011
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
41.7M
IPO Year
2024
1996

Fundamental Metrics

Financial Performance
Metric
GAME
VERU
Price
$0.32
$2.57
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
1.1M
75.1K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
37.72
N/A
EPS
N/A
N/A
Revenue
$96,198,101.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$16.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
85.00
N/A
52 Week Low
$0.26
$0.36
52 Week High
$2.87
$4.59

Technical Indicators

Market Signals
Indicator
GAME
VERU
Relative Strength Index (RSI) 46.19 54.12
Support Level $0.27 $2.15
Resistance Level $0.33 $2.80
Average True Range (ATR) 0.03 0.17
MACD 0.01 0.03
Stochastic Oscillator 56.59 69.92

Price Performance

Historical Comparison
GAME
VERU

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: